HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 7, 2010, Pages 2878-2885

  Lisovsky, Irene ^a,b   Schader, Susan M ^a,b   Martinez Cajas, Jorge Luis ^a,c,d   Oliveira, Maureen ^a   Moisi, Daniela ^a   Wainberg, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CODON; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; OLIGOPEPTIDE; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1; PYRIDINE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CODON; DNA POLYMORPHISM; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS REPLICATION; CELL CULTURE; CELL LINE; DRUG EFFECTS; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HIV INFECTIONS; HUMAN; PHYSIOLOGY; VIROLOGY;

ANTI-HIV AGENTS; CELL LINE; CELLS, CULTURED; CODON; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HUMANS; LOPINAVIR; NELFINAVIR; OLIGOPEPTIDES; POLYMORPHISM, GENETIC; PYRIDINES; PYRIMIDINONES;

EID: 77953764574     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01828-09     Document Type: Article

References (42)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291. (Pubitemid 16013975)
2. Arien, K. K., G. Vanham, and E. J. Arts. 2007. Is HIV-1 evolving to a less virulent form in humans? Nat. Rev. Microbiol. 5:141-151.
3. Bessong, P. O. 2008. Polymorphisms in HIV-1 subtype C proteases and the potential impact on protease inhibitors. Trop. Med. Int. Health 13:144-151.
4. Brenner, B., D. Turner, M. Oliveira, D. Moisi, M. Detorio, M. Carobene, R. G. Marlink, J. Schapiro, M. Roger, and M. A. Wainberg. 2003. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 17:F1-F5.
5. Buonaguro, L., M. L. Tornesello, and F. M. Buonaguro. 2007. Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J. Virol. 81:10209-10219.
6. Camacho, R., A. Godinho, P. Gomes, A. Abecasis, A. M. Vandamme, C. Palma, A. P. Carvalho, J. Cabanas, and J. Gonçalves. 2005. Different substitutions under drug pressure at protease codon 82 in HIV-1 subtype G compared to subtype B infected individuals including a novel I82M resistance mutation. Antivir. Ther. 10:S151.
7. Chaix, M. L., F. Rouet, K. A. Kouakoussui, R. Laguide, P. Fassinou, C. Montcho, S. Blanche, C. Rouzioux, and P. Msellati. 2005. Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Cote d'Ivoire. Pediatr. Infect. Dis. J. 24:1072-1076.
8. Clavel, F., and A. J. Hance. 2004. HIV drug resistance. N. Engl. J. Med. 350:1023-1035.
9. Clemente, J. C., R. Hemrajani, L. E. Blum, M. M. Goodenow, and B. M. Dunn. 2003. Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N. Biochemistry 42:15029-15035.
10. Doualla-Bell, F., A. Avalos, T. Gaolathe, M. Mine, S. Gaseitsiwe, N. Ndwapi, V. A. Novitsky, B. Brenner, M. Oliveira, D. Moisi, H. Moffat, I. Thior, M. Essex, and M. A. Wainberg. 2006. Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen. Antimicrob. Agents Chemother. 50:2210-2213.
11. Doyon, L., G. Croteau, D. Thibeault, F. Poulin, L. Pilote, and D. Lamarre. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70:3763-3769.
12. Grossman, Z., V. Istomin, D. Averbuch, M. Lorber, K. Risenberg, I. Levi, M. Chowers, M. Burke, N. B. Yaacov, and J. M. Schapiro. 2004. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS 18:909-915.
13. Grossman, Z., E. E. Paxinos, D. Averbuch, S. Maayan, N. T. Parkin, D. Engelhard, M. Lorber, V. Istomin, Y. Shaked, E. Mendelson, D. Ram, C. J. Petropoulos, and J. M. Schapiro. 2004. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob. Agents Chemother. 48:2159-2165.
14. Hemelaar, J., E. Gouws, P. D. Ghys, and S. Osmanov. 2006. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20:W13-W23.
15. Holguin, A., C. Sune, F. Hamy, V. Soriano, and T. Klimkait. 2006. Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. J. Clin. Virol. 36:264-271.
16. Kantor, R., D. A. Katzenstein, B. Efron, A. P. Carvalho, B. Wynhoven, P. Cane, J. Clarke, S. Sirivichayakul, M. A. Soares, J. Snoeck, C. Pillay, H. Rudich, R. Rodrigues, A. Holguin, K. Ariyoshi, M. B. Bouzas, P. Cahn, W. Sugiura, V. Soriano, L. F. Brigido, Z. Grossman, L. Morris, A. M. Vandamme, A. Tanuri, P. Phanuphak, J. N. Weber, D. Pillay, P. R. Harrigan, R. Camacho, J. M. Schapiro, and R. W. Shafer. 2005. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2:e112.
17. Kempf, D. J., J. D. Isaacson, M. S. King, S. C. Brun, Y. Xu, K. Real, B. M. Bernstein, A. J. Japour, E. Sun, and R. A. Rode. 2001. Identifications of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. 75:7462-7469.
18. Korber, B., B. Gaschen, K. Yusim, R. Thakallapally, C. Kesmir, and V. Detours. 2001. Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 58:19-42.
19. Leitner, T., B. Foley, B. Hahn, et al. 2009. HIV sequence compendium. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
20. Loemba, H., B. Brenner, M. A. Parniak, S. Ma'ayan, B. Spira, D. Moisi, M. Oliveira, M. Detorio, M. Essex, and M. A. Wainberg. 2002. Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance. Antiviral Res. 56:129-142.
21. Maguire, M. F., R. Guinea, P. Griffin, S. Macmanus, R. C. Elston, J. Wolfram, N. Richards, M. H. Hanlon, D. J. Porter, T. Wrin, N. Parkin, M. Tisdale, E. Furfine, C. Petropoulos, B. W. Snowden, and J. P. Kleim. 2002. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J. Virol. 76:7398-7406.
22. Marcelin, A. G., P. Flandre, J. Pavie, N. Schmidely, M. Wirden, O. Lada, D. Chiche, J. M. Molina, V. Calvez, and the AI454-176 Jaguar Study Team. 2005. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob. Agents Chemother. 49:1739-1744.
23. Martin, P., J. F. Vickrey, G. Proteasa, Y. L. Jimenez, Z. Wawrzak, M. A. Winters, T. C. Merigan, and L. C. Kovari. 2005. "Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target. Structure 13:1887-1895.
24. Martinez-Cajas, J. L., N. Pant-Pai, M. B. Klein, and M. A. Wainberg. 2008. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev. 10:212-223.
25. Martinez-Cajas, J. L., and M. A. Wainberg. 2007. Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives. Antiviral Res. 76:203-221.
26. Mendoza, C., and V. Soriano. 2004. Resistance to HIV protease inhibitors: mechanisms and clinical consequences. Curr. Drug Metab. 5:321-328.
27. Mochizuki, N., N. Otsuka, K. Matsuo, T. Shiino, A. Kojima, T. Kurata, K. Sakai, N. Yamamoto, S. Isomura, T. N. Dhole, Y. Takebe, M. Matsuda, and M. Tatsumi. 1999. An infectious DNA clone of HIV type 1 subtype C. AIDS Res. Hum. Retroviruses 15:1321-1324.
28. Ode, H., S. Matsuyama, M. Hata, S. Neya, J. Kakizawa, W. Sugiura, and T. Hoshino. 2007. Computational characterization of structural role of the non-active site mutation M36I of human immunodeficiency virus type 1 protease. J. Mol. Biol. 370:598-607.
29. Perno, C. F., A. Cozzi-Lepri, F. Forbici, A. Bertoli, M. Violin, M. Stella Mura, G. Cadeo, A. Orani, A. Chirianni, C. De Stefano, C. Balotta, and A. d'Arminio Monforte. 2004. Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed. J. Infect. Dis. 189:1983-1987.
30. Platt, E. J., K. Wehrly, S. E. Kuhmann, B. Chesebro, and D. Kabat. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophage tropic isolates of human immunodeficiency virus type 1. J. Virol. 72:2855-2864.
31. Rhee, S. Y., R. Kantor, D. A. Katzenstein, R. Camacho, L. Morris, S. Sirivichayakul, L. Jorgensen, L. F. Brigido, J. M. Schapiro, and R. W. Shafer. 2006. HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. AIDS 20:643-651.
32. Rhee, S. Y., M. J. Gonzales, R. Kantor, B. J. Betts, J. Ravela, and R. W. Shafer. 2008. HIV drug resistance database. Stanford University, Stanford, CA. http://hivdb.stanford.edu.
33. Robertson, D. L., J. P. Anderson, J. A. Bradac, J. K. Carr, B. Foley, R. K. Funkhouser, F. Gao, B. H. Hahn, M. L. Kalish, C. Kuiken, G. H. Learn, T. Leitner, F. McCutchan, S. Osmanov, M. Peeters, D. Pieniazek, M. Salminen, P. M. Sharp, S. Wolinsky, and B. Korber. 2000. HIV-1 nomenclature proposal. Science 288:55-56.
34. Salomon, H., A. Belmonte, K. Nguyen, Z. Gu, M. Gelfand, and M. A. Wainberg. 1994. Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1. J. Clin. Microbiol. 32:2000-2002.
35. Snoeck, J., R. Kantor, R. W. Shafer, K. Van Laethem, K. Deforche, A. P. Carvalho, B. Wynhoven, M. A. Soares, P. Cane, J. Clarke, C. Pillay, S. Sirivichayakul, K. Ariyoshi, A. Holguin, H. Rudich, R. Rodrigues, M. B. Bouzas, F. Brun-Vezinet, C. Reid, P. Cahn, L. F. Brigido, Z. Grossman, V. Soriano, W. Sugiura, P. Phanuphak, L. Morris, J. Weber, D. Pillay, A. Tanuri, R. P. Harrigan, R. Camacho, J. M. Schapiro, D. Katzenstein, and A. M. Vandamme. 2006. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob. Agents Chemother. 50:694-701.
36. Takahoko, M., M. Tobiume, K. Ishikawa, W. Ampofo, N. Yamamoto, M. Matsuda, and M. Matsumi. 2001. Infectious DNA clone of HIV type 1 A/G recombinant (CRF02-AG) replicable in peripheral blood mononuclear cells. AIDS Res. Hum. Retroviruses 17:1083-1087.
37. Taylor, B. S., M. E. Sobieszczyk, F. E. McCutchan, and S. M. Hammer. 2008. The challenge of HIV-1 subtype diversity. N. Engl. J. Med. 358:1590-1602.
38. UNAIDS. 2008. 2008 report on the global AIDS epidemic. UNAIDS, Geneva, Switzerland.
39. Velazquez-Campoy, A., M. J. Todd, S. Vega, and E. Freire. 2001. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc. Natl. Acad. Sci. U. S. A. 98:6062-6067.
40. Velazquez-Campoy, A., S. Vega, E. Fleming, U. Bacha, Y. Sayed, H. W. Dirr, and E. Freire. 2003. Protease inhibition in African subtypes of HIV-1. AIDS Rev. 5:165-171. (Pubitemid 37336633)
41. Wei, X., J. M. Decker, H. Liu, Z. Zhang, R. B. Arani, J. M. Kilby, M. S. Saag, X. Wu, G. M. Shaw, and J. C. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
42. Zhang, Y. M., H. Imamichi, T. Imamichi, H. C. Lane, J. Falloon, M. B. Vasudevachari, and N. P. Salzman. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:6662-6670.